Background: The Asthma Quality of Life Questionnaire (AQLQ) includes items assessing the impact of asthma on physical activity. Dupilumab (DPL), a fully human mAb, blocks the shared receptor component of IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VENTURE (NCT02528214), DPL 300mg every 2 weeks (q2w) vs placebo (PBO) reduced oral corticosteroid (OCS) maintenance dose and rate of severe asthma exacerbations and improved pre-bronchodilator FEV1 independently of baseline eosinophil levels as well as health-related quality of life (QoL) in patients (pts) with OCS-dependent, severe asthma. DPL was generally well tolerated. Aim: To assess the effect of DPL on physical activity. Methods: Physical activity-related items on the AQLQ assess the impact of asthma on activity on a scale of 1–7; scores of 6/7 indicate little/no limitation in performing physical activities. The proportion of pts with scores of 6/7 on the 4 physical activity-related AQLQ items (#1, #2, #4, #31) was evaluated at baseline (BL), Week (Wk) 12, and Wk24. Results: Proportion of pts with scores of 6/7 on physical activity-related items was comparable at BL in both groups. DPL pts continuously improved over time, with more DPL vs PBO pts scoring 6/7 at Wk24 (odds ratio 1.92–2.70; all p<0.05; Figure). Conclusion: DPL improved physical activity-related QoL while reducing OCS dose in pts with OCS-dependent, severe asthma.